Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
It is very uncertain whether flutamide 250 mg once to twice daily changes proportion of participants who reported an adverse event compared with metformin 1275 mg to 1700 mg per day (very low certainty).
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
Finasteride 5 mg showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with flutamide 250 mg once to b.i.d. (low certainty).
1 finding from 1 review
Proportion of participants who reported an adverse event · women with hirsutism
It is very uncertain whether finasteride 5 mg changes proportion of participants who reported an adverse event compared with flutamide 250 mg once to b.i.d. (very low certainty).
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
Flutamide 250 mg b.i.d. may leads to higher participant‐reported improvement of hirsutism 4‐point Likert scale compared with placebo (low certainty).
1 finding from 1 review
Adverse effects ‐ complication rate at 1 week after surgery · participants with hidradenitis suppurativa
Gentamicin sponge showed no clear difference in adverse effects ‐ complication rate at 1 week after surgery compared with primary closure alone (moderate certainty).
1 finding from 1 review
Adverse effects ‐ complication rate at 3 months after surgery · participants with hidradenitis suppurativa
Gentamicin sponge showed no clear difference in adverse effects ‐ complication rate at 3 months after surgery compared with primary closure alone (moderate certainty).
1 finding from 1 review
Recurrence after surgery · participants with hidradenitis suppurativa
Gentamicin sponge showed no clear difference in recurrence rate at 3 months after surgery compared with primary closure alone (moderate certainty).
1 finding from 1 review
Primary outcome: Histological complete response ( available‐case analysis) No residual LM in staged excision 2 months post‐treatment · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in primary outcome: Histological complete response (intention‐to‐treat)… compared with imiquimod 5% cream alone (low certainty).
2 findings from 1 review
Discontinuation of treatment due to side effects ( · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review
Secondary outcome: Inflammatory response (number of lesions with grade 2 or 3) Grade 2 or 3 Inflammation² · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel may leads to higher secondary outcome: Inflammatory response (number of lesions with… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review